Premium
Excess mortality persists in patients with rheumatoid arthritis
Author(s) -
Lee YeonKyung,
Ahn Ga Young,
Lee Jiyoung,
Shin JungMin,
Lee TaeHan,
Park Dae Jin,
Song YeoJin,
Kim Mi Kyung,
Bae SangCheol
Publication year - 2021
Publication title -
international journal of rheumatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 41
eISSN - 1756-185X
pISSN - 1756-1841
DOI - 10.1111/1756-185x.14058
Subject(s) - medicine , rheumatoid arthritis , standardized mortality ratio , mortality rate , population , cohort , epidemiology , erythrocyte sedimentation rate , confidence interval , cause of death , disease , rheumatology , environmental health
Objectives To investigate the causes and risk of death in a large cohort of Korean patients with rheumatoid arthritis (RA). Methods Patients in the Hanyang BAE (Bae registry of Autoimmune diseases for Epidemiology) RA cohort who fulfilled the American College of Rheumatology criteria were analyzed. A total of 2355 patients were enrolled from October 2001 to December 2015. Mortality data were derived by linking with data from the Korean National Statistical Office. Standardized mortality ratio was estimated by dividing observed deaths by expected number of deaths in the general population. Results Over the observation period, 225 deaths were reported. Total age‐ and sex‐adjusted standardized mortality ratio was 1.65 (95% confidence interval 1.44‐1.87). The most common cause of death was malignancy (40 cases; 17.8%), followed by respiratory disease (38 cases; 16.9%) and cardiovascular disease (32 cases; 14.2%). Mortality rate and causes of death differed according to year and age of RA onset. Compared with survivors, individuals who died were more likely to be male, smokers, diagnosed with RA at an older age, and to have long disease duration, higher erythrocyte sedimentation rate and C‐reactive protein, higher rheumatoid factor positivity rate, more severe radiographic damage, and more comorbidities. Conclusion The mortality rate of patients with RA remains higher than that of the general population. Therefore, to improve the survival of patients with RA, attention should be paid to the management of comorbidities as well as to the RA itself.